Grand Pharmaceutical Group (HKSE:00512) Debt-to-Equity : 0.23 (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Grand Pharmaceutical Group Debt-to-Equity?

Grand Pharmaceutical Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$2,353 Mil. Grand Pharmaceutical Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,052 Mil. Grand Pharmaceutical Group's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$15,158 Mil. Grand Pharmaceutical Group's debt to equity for the quarter that ended in Dec. 2023 was 0.22.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Grand Pharmaceutical Group's Debt-to-Equity or its related term are showing as below:

HKSE:00512' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.21 Med: 0.34 Max: 2.75
Current: 0.23

During the past 13 years, the highest Debt-to-Equity Ratio of Grand Pharmaceutical Group was 2.75. The lowest was 0.21. And the median was 0.34.

HKSE:00512's Debt-to-Equity is ranked better than
57.04% of 845 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs HKSE:00512: 0.23

Grand Pharmaceutical Group Debt-to-Equity Historical Data

The historical data trend for Grand Pharmaceutical Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grand Pharmaceutical Group Debt-to-Equity Chart

Grand Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.25

0.21

0.27

0.32

0.23

Grand Pharmaceutical Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.27	0.26	0.32	0.29	0.23

Competitive Comparison of Grand Pharmaceutical Group's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grand Pharmaceutical Group's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Grand Pharmaceutical Group's Debt-to-Equity falls into.

Grand Pharmaceutical Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Grand Pharmaceutical Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2352.597	+	1051.642)	/	15157.718
	=	0.22

Grand Pharmaceutical Group's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2352.597	+	1051.642)	/	15157.718
	=	0.22

Grand Pharmaceutical Group (HKSE:00512) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Grand Pharmaceutical Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Grand Pharmaceutical Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Grand Pharmaceutical Group (HKSE:00512) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grand Pharmaceutical Group Ltd (HKSE:00512) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MX6A:Germany

Address

99 Queen's Road, Units 3302, 33rd Floor, The Center, Central, Hong Kong, HKG

Website

http://www.chinagrandpharm.com

Grand Pharmaceutical Group Ltd, formerly China Grand Pharmaceutical and Healthcare Holdings Ltd is a drug manufacturer. The company through its subsidiaries manufactures and sells pharmaceutical preparations and medical devices, biotechnology products, nutrition products, specialized pharmaceutical raw materials, and other products. Geographically, it derives a majority of revenue from China and also has a presence in America; Europe; Asia other than the PRC and others.

Grand Pharmaceutical Group (HKSE:00512) Headlines

No Headlines